Rocket

5 articles about Rocket

• Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

  11/26/2018

  Rocket (Nasdaq:RCKT), a leading U.S.-based multi-platform gene therapy company, andREGENXBIO (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease

• Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights

  3/6/2018

  Rocket enters 2018 as a public company with solid financial position following successful completion of merging with Inotek Pharmaceuticals.

• Rocket Pharmaceuticals Prices Public Offering of Common Stock

  1/24/2018

  Rocket today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $13.25 per share.

• Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

  1/24/2018

  Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.

• Inotek Announces Merger Agreement With Rocket To Advance Pipeline Of First-In-Class Gene Therapies For Rare Diseases

  9/13/2017